Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) shares saw strong trading volume on Friday . 205,826 shares were traded during mid-day trading, an increase of 209% from the previous session's volume of 66,630 shares.The stock last traded at $20.56 and had previously closed at $20.50.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on ORKA. Leerink Partners started coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They issued an "outperform" rating and a $44.00 target price for the company. Lifesci Capital initiated coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued an "outperform" rating and a $41.00 target price on the stock. TD Cowen began coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set a "buy" rating for the company. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, October 31st. Finally, Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a "buy" rating and a $40.00 target price for the company. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Oruka Therapeutics has a consensus rating of "Buy" and a consensus target price of $43.17.
Check Out Our Latest Stock Analysis on ORKA
Oruka Therapeutics Price Performance
The company's 50-day simple moving average is $26.25. The company has a market cap of $726.23 million, a P/E ratio of -3.28 and a beta of 0.87.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at about $343,000. Frazier Life Sciences Management L.P. purchased a new stake in Oruka Therapeutics in the 3rd quarter worth $11,699,000. Wellington Management Group LLP purchased a new stake in shares of Oruka Therapeutics during the third quarter worth about $2,013,000. RTW Investments LP bought a new stake in Oruka Therapeutics during the 3rd quarter valued at approximately $45,359,000. Finally, Redmile Group LLC purchased a new position in Oruka Therapeutics in the 3rd quarter worth approximately $10,091,000. Hedge funds and other institutional investors own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
